SITC 29th Annual Meeting

The SITC 2014 Annual Meeting Presentation Archive is supported through a generous contribution from Prometheus Laboratories Inc.

Access slide decks and video via the links in the schedule below.

PDF = click on presentation title to view .pdf version of slides.

VIDEO = presentation video is available. Click on the icon to view video. (Note: if no .pdf version is available for a given presentation, video will be linked from the presentation title.)

Friday, November 7, 2014

7:15 am – 8:00 am Meet-the-Expert Breakfast (Early Career Scientist Event)
0 AMA PRA Category 1 Credits™ (not CME-certified)
7:15 am – 8:00 am Meet-the-Expert Breakfast (Early Career Scientist Event)
0 AMA PRA Category 1 Credits™ (not CME-certified)
 8:00 am – 8:35 am Presidential Welcome and Update Session
.5 AMA PRA Category 1 Credits™
8:00 am – 8:05 am Presidential Welcome  PDF  VIDEO
Francesco M. Marincola, MD – Sidra Medical and Research Center
8:05 am – 8:20 am Update Session: U.S. Food and Drug Administration  PDF
Raj K. Puri, MD, PhD – U.S. Food and Drug Administration
8:20 am – 8:35 am Update Session: National Cancer Institute  PDF
William D. Merritt, PhD – National Cancer Institute
8:35 am – 9:25 am Richard V. Smalley, MD Memorial Lectureship: Cancer as a Disease of the Metaorganism
.75 AMA PRA Category 1 Credits™
8:35 am – 8:40 am Introduction  VIDEO
Francesco M. Marincola, MD – Sidra Medical and Research Center
8:40 am – 9:25 am Cancer as a Disease of the Metaorganism  PDF
Giorgio Trinchieri, MD – National Cancer Institute
9:25 am – 12:00 pm Inflammation, Innate Immunity and Microbiome
2.25 AMA PRA Category 1 Credits
Co-Chairs:
Marco Colonna, MD – Washington University
William J. Murphy, PhD – University of California-Davis
9:25 am – 9:30 am Session Overview  VIDEO
William J. Murphy, PhD – University of California-Davis
 9:30 am – 9:55 am Natural Killer Cell Subsets in Immune Regulation and Tumor Immunity  PDF  VIDEO
William J. Murphy, PhD – University of California-Davis
9:55 am – 10:20 am Natural Killer Cells and Innate Lymphoid Cells in Inflammation and Cancer  PDF  VIDEO
Marco Colonna, MD – Washington University
10:20 am – 10:40 am Break
10:40 am – 10:55 am Direct Activation of STING in the Tumor Microenvironment with Synthetic Cyclic Dinucleotide Derivatives Leads to Potent and Systemic Tumor-Specific Immunity
Leticia Corrales, PhD – University of Chicago
10:55 am – 11:10 am Evidence Implicating the Commensal Microbiota in Shaping Anti-Tumor Immunity in Melanoma
Ayelet Sivan – University of Chicago
11:10 am – 11:35 am The Role of the Intestinal Microbiome on GVHD  PDF
Marcel R.M. van den Brink, MD, PhD – Memorial Sloan-Kettering
Cancer Center
11:35 am – 12:00 pm Roles of the Microbiota in Immunity and Inflammation
Yasmine Belkaid, PhD – National Institutes of Health
12:00 pm – 12:30 pm Late-Breaking Abstract Session
0 AMA PRA Category 1 Credits™ (not CME-certified)
12:00 pm – 12:15 pm TCR Repertoire Divergence Reflects Microenvironmental Immune Phenotypes in Glioma  PDF
Jennifer Sims, PhD – Columbia University
12:15 pm – 12:30 pm Activation of Toll-Like Receptor-2 by Tumor Associated Matrix Metalloproteinase-2 Modulates Dendritic Cell Function
Nina Bhardwaj, MD PhD – Icahn School of Medicine at Mt. Sinai
12:30 pm – 2:00 pm Lunch, Poster Viewing and Exhibits
Oral Poster Session 12:50 pm – 1:40 pm
2:00 pm – 4:15 pm Lung Cancer: Immunology and Immunotherapy
2.25 AMA PRA Category 1 Credits™
Co-Chairs:
Roy S. Herbst, MD, PhD – Yale Cancer Center
Laurence Zitvogel, MD, PhD – Institute Gustave Roussy
2:00 pm – 2:05 pm Session Overview
Laurence Zitvogel, MD, PhD – Institute Gustave Roussy
2:05 pm – 2:30 pm Personalizing Lung Cancer Immunotherapy
Laurence Zitvogel, MD, PhD – Institute Gustave Roussy
2:30 pm – 2:55 pm Personalized Immunotherapy for Non-Small Cell Lung Cancer  PDF  VIDEO
Roy S. Herbst, MD, PhD – Yale Cancer Center
2:55 pm – 3:10 pm TG4010 Immunotherapy Combined with First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase IIb Results of the TIME Study  PDF  VIDEO
John Nemunaitis, MD – Mary Crowley Medical Research Center
3:10 pm – 3:25 pm PD-L1 Expression Correlates with Immune Response in a Phase I Trial of CCL21 Gene Modified Dendritic Cell Therapy in Lung Cancer
Jay M. Lee, MD – University of California, Los Angeles
3:25 pm – 3:50 pm Manipulating Tumor-Immune Cell Interactions in NSCLC
Mikael J. Pittet, PhD – Mass General Hospital
3:50 pm – 4:15 pm PD-1 Immune Checkpoint Blockade: Patient Characteristics and Biomarkers Associated with Response  PDF  VIDEO
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
4:15 pm – 4:45 pm Break
4:45 pm – 6:10 pm Concurrent Session — Tumor Microenvironment and Immunosuppression
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Suzanne Ostrand-Rosenberg, PhD – University of Maryland Baltimore County
Weiping Zou, MD, PhD – University of Michigan
4:45 pm – 4:50 pm Session Overview
Suzanne Ostrand-Rosenberg, PhD – University of Maryland Baltimore County
4:50 pm – 5:10 pm Neutralizing Immune Suppression in the Tumor Microenvironment
Suzanne Ostrand-Rosenberg, PhD – University of Maryland Baltimore County
5:10 pm – 5:35 pm Integrating Immunoregulatory and Vascular Signaling Programs Through Lectin-Glycan Interactions  PDF
Gabriel A. Rabinovich, PhD – Instituto de Biología y Medicina Experimental (IBYME)
5:35 pm – 5:55 pm Immune Impact on Cancer Stemness  PDF  VIDEO
Weiping Zou, MD, PhD – University of Michigan
5:55 pm – 6:10 pm FcgRIIIA (CD16)-Expressing Monocytes Mediate the Depletion of Tumor-Infiltrating Tregs Via Ipilimumab-Dependent ADCC in Melanoma Patients  PDF
Emanuela Romano, MD, PhD – University Hospital of Lausanne
4:45 pm – 6:10 pm Concurrent Session — Immunopotentiation by Radiotherapy: Mechanisms and Opportunities
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Sandra Demaria, MD – New York University
Susan Knox, MD, PhD – Stanford University
4:45 pm – 4:50 pm Session Overview  VIDEO
Susan Knox, MD, PhD – Stanford University
4:50 pm – 5:15 pm New Directions with NKT Cells and Nanoscale Flow Cytometry
Jennifer Clare Jones, MD, PhD – National Cancer Institute
5:15 pm – 5:40 pm Radiotherapy with TGF-β Blockade Jump-Starts Tumor-Specific T Cells and Immune Checkpoint Inhibitors Keep Them Going  PDF  VIDEO
Sandra Demaria, MD – New York University
5:40 pm – 5:55 pm The Anti-Tumor Immune Response Generated by Radiation Therapy May be Limited by Tumor Cell Adaptive Resistance and can be Circumvented by PD-L1 Blockade  PDF  VIDEO
Simon Dovedi, PhD, MSc, BSC – University of Manchester
5:55 pm – 6:10 pm CD47 Limits Cooperation between Adaptive Tumor Immunity and Radiation Therapy  PDF  VIDEO
David D. Roberts, PhD – National Cancer Institute

Saturday, November 8, 2014

8:00 am – 8:35 am Welcome and Update Session
.5 AMA PRA Category 1 Credits™
8:00 am – 8:05 am Welcome and Overview  VIDEO
Kim A. Margolin, MD – Stanford University
8:05 am – 8:10 am Update Session: SITC Biomarkers Task Force  PDF  VIDEO
Lisa H. Butterfield, PhD – University of Pittsburgh
8:10 am – 8:35 am Update Session: Cancer Immunotherapy Trials Network
Martin A. Cheever, MD – Fred Hutchinson Cancer Research Center
8:35 am – 9:25 am Keynote Address: Prophylactic Cancer Vaccines - Feasibility and Progress
.75 AMA PRA Category 1 Credits™
Olivera J. Finn, PhD – University of Pittsburgh
9:25 am – 12:00 pm Barriers to Successful Vaccines
2.25 AMA PRA Category 1 Credits™
Co-Chairs:
Jonathan L. Bramson, PhD – McMaster University
Daniel E. Speiser, MD – Ludwig Center for Cancer Research of the University of Lausanne
9:25 am – 9:45 am Session Overview  VIDEO
Daniel E. Speiser, MD – Ludwig Center for Cancer Research of the University of Lausanne
9:45 am – 10:05 am Immunotherapy and the Immunosuppressive Tumor Network
Gosse J. Adema, PhD – Radboud University Medical Center
10:05 am – 10:25 am Antigen-Specific T Cell Responses to Breast Cancer  PDF
Jill E. Slansky, PhD – University of Colorado
10:25 am – 10:45 am Break
10:45 am – 11:00 am Functional Redundancy of PI3K Isoforms in Conventional T Cells Provides a Selective Treg-Targeting Strategy Through Inhibition of PI3K-Delta Isoform
Shamim Ahmad, PhD – Georgia Regents University Cancer Center
11:00 am – 11:15 am Vaccine Targeting HIF1A in Triple Negative Breast Cancer  PDF  VIDEO
Mary L. Disis, MD, FACP – University of Washington
11:15 am – 11:35 am Local, Regional, and Systemic Effects of TLR Agonists and IFA as Adjuvants for Peptide Vaccines  PDF
Craig L. Slingluff, Jr., MD – University of Virginia
11:35 am – 11:55 am The Use of Peptides in the Therapeutic Vaccination of Cancer  PDF  VIDEO
Hans-Georg Rammensee, PhD – Universitäet Tüebingen
11:55 am – 12:00 pm Closing Remarks   VIDEO
Daniel E. Speiser, MD – Ludwig Center for Cancer Research of the University of Lausanne
12:00 pm – 12:30 pm Late-Breaking Abstract Session
0 AMA PRA Category 1 Credits™ (not CME-certified)
12:00 pm – 12:15 pm DNA Vaccine VGX-3100 with Electroporation Induces Regression of Cervical Intraepithelial Neoplasia 2/3 and Clears HPV Infection with Robust T Cell Responses: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial  PDF
Laurent M. Humeau, PhD – Inovio Pharmaceuticals
12:15 pm – 12:30 pm OX40 Agonist Immunotherapy Expands Tumor Reactive CD8 T Cells with a Unique T Cell Receptor Repertoire and Synergizes with PDL1 Blockade to Promote Tumor Regression  PDF
Amy E. Moran, PhD – Earle A. Chiles Cancer Research Institute, Providence Cancer Center
12:30 pm – 2:00 pm Lunch, Poster Viewing and Exhibits
O
ral Poster Session 12:50 pm – 1:50 pm
2:00 pm – 3:05 pm Presidential Session
1.0 AMA PRA Category 1 Credits™
2:00 pm – 2:05 pm Introduction  VIDEO
Francesco M. Marincola, MD – Sidra Medical and Research Center
2:05 pm – 2:20 pm Tumor Derived Stress Triggers C/EBPβ Homologous Protein (CHOP) Expression in Myeloid Derived Suppressor Cells (MDSC) and Mediates Immunosuppressive Activity  PDF
Paul Thevenot, PhD – Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center
2:20 pm – 2:35 pm Mechanisms of TIGIT-Driven Immune Suppression in Cancer
Sema Kurtulus, PhD – Center for Neurologic Diseases Brigham &
Women’s Hospital
2:35 pm – 2:50 pm Melanoma-Intrinsic B-Catenin Signaling Prevents T Cell Infiltration and Anti-Tumor Immunity
Stefani Spranger, PhD – University of Chicago
2:50 pm – 3:05 pm Pre-Clinical Validation of a Humanized Anti-EGFR Variant III Chimeric Antigen Receptor and Phase I Trial of CART-EGFRvIII in Glioblastoma
Marcela Maus, MD, PhD – University of Pennsylvania
3:05 pm – 3:25 pm Immunoscore Update  PDF  VIDEO
.25 AMA PRA Category 1 Credits™
Bernard A. Fox, PhD – Earle A. Chiles Cancer Research Institute,
Providence Cancer Center
3:25 pm – 4:00 pm Break
4:00 pm – 5:25 pm Concurrent Session — Coinhibition and Costimulation: Targets and Strategies
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Walter J. Urba, MD, PhD – Earle A. Chiles Research Institute,
Providence Cancer Center
Robert H. Vonderheide, MD, DPhil – University of Pennsylvania
4:00 pm – 4:05 pm Session Overview  VIDEO
Walter J. Urba, MD, PhD – Earle A. Chiles Research Institute,
Providence Cancer Center
4:05 pm – 4:30 pm OX40 Immunotherapy in Cancer Patients: Immunological Observations and Implications for T Cell Immunotherapy  PDF  VIDEO
Brendan D. Curti, MD – Earle A. Chiles Research Institute, Providence
Cancer Center
4:30 pm – 4:45 pm Distinct Immunologic Changes In Vivo Following Combination Versus Individual PD-1 or CTLA-4 Checkpoint Blockade in Human Cancer
Kavita Dhodapkar, MD – Yale University
4:45 pm – 5:00 pm Melanoma Progression is Associated with NK Cell Exhaustion
Ines Pires da Silva, MD – New York University Cancer Center
5:00 pm – 5:25 pm CD40 Agonists in Cancer Immunotherapy  PDF  VIDEO
Robert H. Vonderheide, MD, DPhil – University of Pennsylvania
4:00 pm – 5:25 pm Concurrent Session — High Throughput Technologies: Determinants of the Immune Response to Cancer
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Katherine L. Nathanson, MD – University of Pennsylvania
Paul F. Robbins, PhD National Institutes of Health/National Cancer Institute
4:00 pm – 4:05 pm Session Overview  PDF  VIDEO
Katherine L. Nathanson, MD – University of Pennsylvania
4:05 pm – 4:30 pm Use of High Throughput Sequencing to Identify Mutated Tumor Antigens  PDF  VIDEO
Paul F. Robbins, PhD National Institutes of Health/National Cancer Institute
4:30 pm – 4:50 pm Inherited Genetic Response
Kevin M. Brown, PhD – National Cancer Institute
4:50 pm – 5:10 pm Single Cell Functional Analysis Provides Insights into Cancer Patient Responses, including the Development of Resistance, to Cell-Based and Combination Immunotherapies  PDF  VIDEO
James R. Heath, PhD – California Institute of Technology
5:10 pm – 5:25 pm T Cell Receptor Diversity Evaluation to Predict Patient Response to Ipilimumab in Metastatic Melanoma  PDF  VIDEO
Michael Postow, MD – Memorial Sloan-Kettering Cancer Center

Sunday, November 9, 2014

8:00 am – 10:15 am Adoptive Immunotherapy
2.25 AMA PRA Category 1 Credits™
Co-Chairs:
Helen E. Heslop, MD – Baylor College of Medicine
Per thor Straten, PhD – Centre for Cancer Immune Therapy (CCIT)
8:00 am – 8:05 am Session Overview  VIDEO
Helen E. Heslop, MD – Baylor College of Medicine
8:05 am – 8:30 am Moving Tumor Infiltrating Lymphocytes and Biomarkers Forward  PDF  VIDEO
Patrick Hwu, MD – University of Texas, MD Anderson Cancer Center
8:30 am – 8:55 am Melanoma Therapy using Adoptive Transfer of Expanded Tumor Infiltrating T cells; Prospects and Pitfalls  PDF  VIDEO
Per thor Straten, PhD – Centre for Cancer Immune Therapy (CCIT)
8:55 am – 9:10 am Toward Cell Transfer Immunotherapy Against Patient-Specific Mutations in Gastrointestinal Cancers  PDF
Eric Tran, PhD – National Insitutes of Health/National Cancer
Institute
9:10 am – 9:25 am Modulating Immunometabolism of Tumor Specific CD8 T Cells to Enhance T Cell Based Therapy for Cancer  PDF  VIDEO
Madhusudhanan Sukumar, PhD – National Cancer Institute
9:25 am – 9:50 am Enhancing the IQ of CAR T Cells  PDF  VIDEO
Michael C.V. Jensen, MD – University of Washington
9:50 am – 10:15 am CAR Therapy: The CD19 Paradigm
Michel Sadelain, MD, PhD – Memorial Sloan-Kettering Cancer Center
10:15 am Annual Meeting Adjourns

Creative Commons License
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.